Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880159 | 0.88 | ALDH1A1 (0.52) | MAPK1NLRP3KDM4EALDH1A1CA1 | |
| SCHEMBL11460936 | 0.84 | MAPK1 (0.69) | MAPK1TSHRAPEX1ALDH1A1 | |
| SCHEMBL3873090 | 0.84 | MAPK1 (0.56) | MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13545228 | 0.84 | NLRP3 (0.50) | MAPK1TSHRNLRP3ALDH1A1CA1 | |
| SCHEMBL13543282 | 0.84 | NLRP3 (0.47) | MAPK1TSHRNLRP3ALDH1A1CA1 | |
| SCHEMBL3874483 | 0.84 | MAPK1 (0.46) | MAPK1TSHRKDM4EPOLBALDH1A1 | |
| SCHEMBL5038257 | 0.83 | S1PR3 (0.53) | MAPK1TSHRNLRP3POLB | |
| SCHEMBL1813497 | 0.82 | TNNI3K (0.47) | MAPK1TSHRKDM4EPOLB | |
| SCHEMBL987275 | 0.82 | LMNA (0.60) | MAPK1TSHRAPEX1KDM4EPOLB | |
| SCHEMBL10722381 | 0.81 | GAA (0.55) | MAPK1TSHRNLRP3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-5246942-A | Central nervous system, anti-emetic and gastric prokinetic activity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0494140-A4 | DIBENZOFURANCARBOXAMIDES | — | 1992-09-02 | — | — | EP | disclosed |
| EP-0494140-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-07-15 | — | — | EP | disclosed |
| WO-1991004738-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4959485-A | 5-HT3 ANTAGONISTS | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| US-4935511-A | Nervous system, gastrointestinal disorders | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| WO-1989010364-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-11-02 | — | — | WO | disclosed |
| EP-0339950-A2 | Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4863921-A | Dibenzofurancarboxamides and their pharmaceutical compositions and methods | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4816471-A | NERVOUS SYSTEM DISORDERS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILLE-DE FRANCE (FR) | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | CYP2B6, CYP2D6, CYP1A2 | MAPK1 2206/4885TSHR 1683/4885APEX1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.